These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 14965203)

  • 21. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
    Robinson JG
    Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthetic statins: more data on newer lipid-lowering agents.
    Wierzbicki AS
    Curr Med Res Opin; 2001; 17(1):74-7. PubMed ID: 11464449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?
    Ray KK; Cannon CP; Ganz P
    Am J Cardiol; 2006 Dec; 98(11A):18P-25P. PubMed ID: 17126675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
    Bruckert E; Ferrières J
    Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and dangers of statin therapy.
    Maritz FJ
    Cardiovasc J S Afr; 2002; 13(4):200-3. PubMed ID: 12389064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of statins in reversing atherosclerosis: what the latest regression studies show.
    Grines CL
    J Interv Cardiol; 2006 Feb; 19(1):3-9. PubMed ID: 16483333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pleiotropic effects of statins in atherosclerosis and diabetes.
    Bellosta S; Ferri N; Arnaboldi L; Bernini F; Paoletti R; Corsini A
    Diabetes Care; 2000 Apr; 23 Suppl 2():B72-8. PubMed ID: 10860194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
    Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Atherosclerosis in light of the evidence from large statin trials].
    Cortese C; Bernardini S; Motti C
    Ann Ital Med Int; 2000; 15(1):103-7. PubMed ID: 10842899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Statins and stroke.
    Endres M
    J Cereb Blood Flow Metab; 2005 Sep; 25(9):1093-110. PubMed ID: 15815580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Managing hyperlipidemia: current and future roles of HMG-CoA reductase inhibitors.
    Lopez LM
    Am J Health Syst Pharm; 2002 Jun; 59(12):1173-9; quiz 1180-2. PubMed ID: 12073858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beyond the laboratory: clinical implications for statin pleiotropy.
    Halcox JP; Deanfield JE
    Circulation; 2004 Jun; 109(21 Suppl 1):II42-8. PubMed ID: 15173062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current, new and future treatments in dyslipidaemia and atherosclerosis.
    Chong PH; Bachenheimer BS
    Drugs; 2000 Jul; 60(1):55-93. PubMed ID: 10929930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The care gap: underuse of statin therapy in the elderly.
    Gaw A
    Int J Clin Pract; 2004 Aug; 58(8):777-85. PubMed ID: 15372851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The pleiotropic effects of statins].
    Wolfovitz E
    Harefuah; 2005 Aug; 144(8):577-82, 597. PubMed ID: 16146158
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of sphingosine-1-phosphate signalling as a potential underlying mechanism of the pleiotropic effects of statin therapy.
    Egom EE; Rose RA; Neyses L; Soran H; Cleland JG; Mamas MA
    Crit Rev Clin Lab Sci; 2013; 50(3):79-89. PubMed ID: 23885725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Can statins slow the process of vascular calcification? Possibilities of lipid-lowering therapy and pleiotropic effect by statin treatment].
    Iijima K; Ouchi Y
    Clin Calcium; 2010 Nov; 20(11):1719-28. PubMed ID: 21037393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pitavastatin - from clinical trials to clinical practice.
    Masana L
    Atheroscler Suppl; 2010 Dec; 11(3):15-22. PubMed ID: 21193154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.